iCAD (NASDAQ:ICAD) Upgraded by StockNews.com to “Hold” Rating

StockNews.com upgraded shares of iCAD (NASDAQ:ICAD) from a sell rating to a hold rating in a report published on Thursday morning.

iCAD Stock Down 6.6 %

Shares of NASDAQ:ICAD opened at $2.83 on Thursday. iCAD has a fifty-two week low of $1.18 and a fifty-two week high of $3.78. The company has a market cap of $75.11 million, a PE ratio of -21.77 and a beta of 1.47. The company’s 50-day moving average price is $2.46 and its 200 day moving average price is $1.93.

Hedge Funds Weigh In On iCAD

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. waypoint wealth counsel boosted its position in iCAD by 44.0% during the 4th quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock worth $26,000 after acquiring an additional 4,400 shares during the period. Thompson Davis & CO. Inc. bought a new stake in shares of iCAD during the fourth quarter valued at about $31,000. PKS Advisory Services LLC bought a new stake in shares of iCAD during the fourth quarter valued at about $53,000. Wells Fargo & Company MN grew its position in iCAD by 51.3% in the 4th quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company’s stock valued at $72,000 after buying an additional 13,402 shares in the last quarter. Finally, Integrated Wealth Concepts LLC acquired a new position in iCAD during the 4th quarter valued at about $92,000. 24.61% of the stock is owned by institutional investors.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.